(cid:38)(cid:68)(cid:86)(cid:72)(cid:22)(cid:29)(cid:19)(cid:26)(cid:16)(cid:70)(cid:89)(cid:16)(cid:19)(cid:19)(cid:24)(cid:25)(cid:26)(cid:16)(cid:48)(cid:48)(cid:38)(cid:3)(cid:3)(cid:3)(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:22)(cid:22)(cid:28)(cid:3)(cid:3)(cid:3)(cid:3)(cid:41)(cid:76)(cid:79)(cid:72)(cid:71)(cid:19)(cid:22)(cid:18)(cid:20)(cid:22)(cid:18)(cid:19)(cid:28)(cid:3)(cid:3)(cid:3)(cid:51)(cid:68)(cid:74)(cid:72)(cid:20)(cid:3)(cid:82)(cid:73)(cid:3)(cid:22)(cid:22)
`
`(cid:45)(cid:68)(cid:80)(cid:72)(cid:86)(cid:3)(cid:45)(cid:17)(cid:3)(cid:40)(cid:79)(cid:68)(cid:70)(cid:84)(cid:88)(cid:68)(cid:3)(cid:11)(cid:38)(cid:54)(cid:37)(cid:3)(cid:49)(cid:82)(cid:17)(cid:3)(cid:20)(cid:27)(cid:26)(cid:27)(cid:28)(cid:26)(cid:12)(cid:3)
`(cid:77)(cid:68)(cid:80)(cid:72)(cid:86)(cid:17)(cid:72)(cid:79)(cid:68)(cid:70)(cid:84)(cid:88)(cid:68)(cid:35)(cid:71)(cid:72)(cid:70)(cid:75)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:82)(cid:80)(cid:3)
`(cid:49)(cid:82)(cid:72)(cid:80)(cid:76)(cid:3)(cid:38)(cid:17)(cid:3)(cid:40)(cid:86)(cid:83)(cid:76)(cid:81)(cid:82)(cid:86)(cid:68)(cid:3)(cid:11)(cid:38)(cid:54)(cid:37)(cid:3)(cid:49)(cid:82)(cid:17)(cid:3)(cid:20)(cid:20)(cid:25)(cid:26)(cid:24)(cid:22)(cid:12)(cid:3)
`(cid:81)(cid:76)(cid:70)(cid:78)(cid:92)(cid:17)(cid:72)(cid:86)(cid:83)(cid:76)(cid:81)(cid:82)(cid:86)(cid:68)(cid:35)(cid:71)(cid:72)(cid:70)(cid:75)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:82)(cid:80)(cid:3)
`(cid:36)(cid:81)(cid:71)(cid:85)(cid:72)(cid:90)(cid:3)(cid:49)(cid:17)(cid:3)(cid:55)(cid:75)(cid:82)(cid:80)(cid:68)(cid:86)(cid:72)(cid:86)(cid:3)(cid:11)(cid:38)(cid:54)(cid:37)(cid:3)(cid:49)(cid:82)(cid:17)(cid:3)(cid:20)(cid:26)(cid:26)(cid:22)(cid:22)(cid:28)(cid:12)(cid:3)
`(cid:68)(cid:81)(cid:71)(cid:85)(cid:72)(cid:90)(cid:17)(cid:87)(cid:75)(cid:82)(cid:80)(cid:68)(cid:86)(cid:72)(cid:86)(cid:35)(cid:71)(cid:72)(cid:70)(cid:75)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:82)(cid:80)(cid:3)
`(cid:48)(cid:76)(cid:70)(cid:75)(cid:72)(cid:79)(cid:79)(cid:72)(cid:3)(cid:58)(cid:17)(cid:3)(cid:60)(cid:68)(cid:81)(cid:74)(cid:3)(cid:11)(cid:38)(cid:54)(cid:37)(cid:3)(cid:49)(cid:82)(cid:17)(cid:3)(cid:21)(cid:20)(cid:24)(cid:20)(cid:28)(cid:28)(cid:12)(cid:3)
`(cid:80)(cid:76)(cid:70)(cid:75)(cid:72)(cid:79)(cid:79)(cid:72)(cid:17)(cid:92)(cid:68)(cid:81)(cid:74)(cid:35)(cid:71)(cid:72)(cid:70)(cid:75)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:82)(cid:80)(cid:3)
`(cid:43)(cid:76)(cid:72)(cid:88)(cid:3)(cid:43)(cid:17)(cid:3)(cid:51)(cid:75)(cid:68)(cid:81)(cid:3)(cid:11)(cid:38)(cid:54)(cid:37)(cid:3)(cid:49)(cid:82)(cid:17)(cid:3)(cid:21)(cid:20)(cid:27)(cid:21)(cid:20)(cid:25)(cid:12)(cid:3)
`(cid:75)(cid:76)(cid:72)(cid:88)(cid:17)(cid:83)(cid:75)(cid:68)(cid:81)(cid:35)(cid:71)(cid:72)(cid:70)(cid:75)(cid:72)(cid:85)(cid:87)(cid:17)(cid:70)(cid:82)(cid:80)(cid:3)
`(cid:39)(cid:40)(cid:38)(cid:43)(cid:40)(cid:53)(cid:55)(cid:3)(cid:47)(cid:47)(cid:51)(cid:3)
`(cid:21)(cid:23)(cid:23)(cid:19)(cid:3)(cid:58)(cid:17)(cid:3)(cid:40)(cid:79)(cid:3)(cid:38)(cid:68)(cid:80)(cid:76)(cid:81)(cid:82)(cid:3)(cid:53)(cid:72)(cid:68)(cid:79)(cid:15)(cid:3)(cid:54)(cid:88)(cid:76)(cid:87)(cid:72)(cid:3)(cid:26)(cid:19)(cid:19)(cid:3)
`(cid:48)(cid:82)(cid:88)(cid:81)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:57)(cid:76)(cid:72)(cid:90)(cid:15)(cid:3)(cid:38)(cid:68)(cid:79)(cid:76)(cid:73)(cid:82)(cid:85)(cid:81)(cid:76)(cid:68)(cid:3)(cid:3)(cid:28)(cid:23)(cid:19)(cid:23)(cid:19)(cid:16)(cid:20)(cid:23)(cid:28)(cid:28)(cid:3)
`(cid:55)(cid:72)(cid:79)(cid:72)(cid:83)(cid:75)(cid:82)(cid:81)(cid:72)(cid:29)(cid:3)
`(cid:11)(cid:25)(cid:24)(cid:19)(cid:12)(cid:3)(cid:27)(cid:20)(cid:22)(cid:16)(cid:23)(cid:27)(cid:19)(cid:19)(cid:3)
`(cid:41)(cid:68)(cid:70)(cid:86)(cid:76)(cid:80)(cid:76)(cid:79)(cid:72)(cid:29)(cid:3)
`(cid:11)(cid:25)(cid:24)(cid:19)(cid:12)(cid:3)(cid:27)(cid:20)(cid:22)(cid:16)(cid:23)(cid:27)(cid:23)(cid:27)(cid:3)
`(cid:36)(cid:87)(cid:87)(cid:82)(cid:85)(cid:81)(cid:72)(cid:92)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:51)(cid:79)(cid:68)(cid:76)(cid:81)(cid:87)(cid:76)(cid:73)(cid:73)(cid:86)(cid:3)
`(cid:48)(cid:40)(cid:39)(cid:55)(cid:53)(cid:50)(cid:49)(cid:44)(cid:38)(cid:15)(cid:3)(cid:44)(cid:49)(cid:38)(cid:17)(cid:15)(cid:3)(cid:48)(cid:40)(cid:39)(cid:55)(cid:53)(cid:50)(cid:49)(cid:44)(cid:38)(cid:3)(cid:56)(cid:54)(cid:36)(cid:15)(cid:3)(cid:44)(cid:49)(cid:38)(cid:17)(cid:15)(cid:3)
`(cid:36)(cid:49)(cid:39)(cid:3)(cid:48)(cid:40)(cid:39)(cid:55)(cid:53)(cid:50)(cid:49)(cid:44)(cid:38)(cid:3)(cid:57)(cid:36)(cid:54)(cid:38)(cid:56)(cid:47)(cid:36)(cid:53)(cid:15)(cid:3)(cid:44)(cid:49)(cid:38)(cid:17)(cid:3)
`(cid:56)(cid:49)(cid:44)(cid:55)(cid:40)(cid:39)(cid:3)(cid:54)(cid:55)(cid:36)(cid:55)(cid:40)(cid:54)(cid:3)(cid:39)(cid:44)(cid:54)(cid:55)(cid:53)(cid:44)(cid:38)(cid:55)(cid:3)(cid:38)(cid:50)(cid:56)(cid:53)(cid:55)(cid:3)
`(cid:49)(cid:50)(cid:53)(cid:55)(cid:43)(cid:40)(cid:53)(cid:49)(cid:3)(cid:39)(cid:44)(cid:54)(cid:55)(cid:53)(cid:44)(cid:38)(cid:55)(cid:3)(cid:50)(cid:41)(cid:3)(cid:38)(cid:36)(cid:47)(cid:44)(cid:41)(cid:50)(cid:53)(cid:49)(cid:44)(cid:36)(cid:3)
`(cid:54)(cid:36)(cid:49)(cid:3)(cid:41)(cid:53)(cid:36)(cid:49)(cid:38)(cid:44)(cid:54)(cid:38)(cid:50)(cid:3)(cid:39)(cid:44)(cid:57)(cid:44)(cid:54)(cid:44)(cid:50)(cid:49)(cid:3)
`
`(cid:48)(cid:40)(cid:39)(cid:55)(cid:53)(cid:50)(cid:49)(cid:44)(cid:38)(cid:15)(cid:3)(cid:44)(cid:49)(cid:38)(cid:17)(cid:15)(cid:3)(cid:68)(cid:3)(cid:48)(cid:76)(cid:81)(cid:81)(cid:72)(cid:86)(cid:82)(cid:87)(cid:68)(cid:3)
`(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:48)(cid:40)(cid:39)(cid:55)(cid:53)(cid:50)(cid:49)(cid:44)(cid:38)(cid:3)(cid:56)(cid:54)(cid:36)(cid:15)(cid:3)(cid:44)(cid:49)(cid:38)(cid:17)(cid:15)(cid:3)(cid:68)(cid:3)
`(cid:48)(cid:76)(cid:81)(cid:81)(cid:72)(cid:86)(cid:82)(cid:87)(cid:68)(cid:3)(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:48)(cid:40)(cid:39)(cid:55)(cid:53)(cid:50)(cid:49)(cid:44)(cid:38)(cid:3)
`(cid:57)(cid:36)(cid:54)(cid:38)(cid:56)(cid:47)(cid:36)(cid:53)(cid:15)(cid:3)(cid:44)(cid:49)(cid:38)(cid:17)(cid:15)(cid:3)(cid:68)(cid:3)(cid:39)(cid:72)(cid:79)(cid:68)(cid:90)(cid:68)(cid:85)(cid:72)(cid:3)
`(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)
`
`(cid:51)(cid:79)(cid:68)(cid:76)(cid:81)(cid:87)(cid:76)(cid:73)(cid:73)(cid:86)(cid:15)
`
`(cid:89)(cid:17)
`(cid:36)(cid:42)(cid:36)(cid:3)(cid:48)(cid:40)(cid:39)(cid:44)(cid:38)(cid:36)(cid:47)(cid:3)(cid:38)(cid:50)(cid:53)(cid:51)(cid:50)(cid:53)(cid:36)(cid:55)(cid:44)(cid:50)(cid:49)(cid:15)(cid:3)(cid:68)(cid:3)
`(cid:48)(cid:76)(cid:81)(cid:81)(cid:72)(cid:86)(cid:82)(cid:87)(cid:68)(cid:3)(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)
`(cid:39)(cid:72)(cid:73)(cid:72)(cid:81)(cid:71)(cid:68)(cid:81)(cid:87)(cid:17)
`
`(cid:38)(cid:68)(cid:86)(cid:72)(cid:3)(cid:49)(cid:82)(cid:17)(cid:3)(cid:38)(cid:19)(cid:26)(cid:16)(cid:19)(cid:19)(cid:24)(cid:25)(cid:26)(cid:3)(cid:48)(cid:48)(cid:38)(cid:3)
`(cid:48)(cid:40)(cid:39)(cid:55)(cid:53)(cid:50)(cid:49)(cid:44)(cid:38)(cid:182)(cid:54)(cid:3)(cid:50)(cid:51)(cid:51)(cid:50)(cid:54)(cid:44)(cid:55)(cid:44)(cid:50)(cid:49)(cid:3)(cid:55)(cid:50)(cid:3)(cid:36)(cid:42)(cid:36)(cid:182)(cid:54)(cid:3)
`(cid:48)(cid:50)(cid:55)(cid:44)(cid:50)(cid:49)(cid:3)(cid:11)(cid:6)(cid:21)(cid:12)(cid:3)(cid:41)(cid:50)(cid:53)(cid:3)(cid:54)(cid:56)(cid:48)(cid:48)(cid:36)(cid:53)(cid:60)(cid:3)
`(cid:45)(cid:56)(cid:39)(cid:42)(cid:48)(cid:40)(cid:49)(cid:55)(cid:3)(cid:50)(cid:41)(cid:3)(cid:44)(cid:49)(cid:57)(cid:36)(cid:47)(cid:44)(cid:39)(cid:44)(cid:55)(cid:60)(cid:3)(cid:56)(cid:49)(cid:39)(cid:40)(cid:53)(cid:3)(cid:22)(cid:24)(cid:3)
`(cid:56)(cid:17)(cid:54)(cid:17)(cid:38)(cid:17)(cid:3)(cid:134)(cid:134)(cid:3)(cid:20)(cid:19)(cid:20)(cid:3)(cid:11)(cid:179)(cid:39)(cid:50)(cid:56)(cid:37)(cid:47)(cid:40)(cid:3)(cid:51)(cid:36)(cid:55)(cid:40)(cid:49)(cid:55)(cid:44)(cid:49)(cid:42)(cid:180)(cid:12)(cid:15)(cid:3)
`(cid:20)(cid:19)(cid:21)(cid:11)(cid:68)(cid:12)(cid:3)(cid:11)(cid:179)(cid:51)(cid:53)(cid:44)(cid:50)(cid:53)(cid:3)(cid:56)(cid:54)(cid:40)(cid:180)(cid:12)(cid:3)(cid:36)(cid:49)(cid:39)(cid:3)(cid:20)(cid:19)(cid:22)(cid:3)
`(cid:11)(cid:179)(cid:50)(cid:37)(cid:57)(cid:44)(cid:50)(cid:56)(cid:54)(cid:49)(cid:40)(cid:54)(cid:54)(cid:12)
`(cid:39)(cid:68)(cid:87)(cid:72)(cid:29)(cid:3) (cid:36)(cid:83)(cid:85)(cid:76)(cid:79)(cid:3)(cid:22)(cid:15)(cid:3)(cid:21)(cid:19)(cid:19)(cid:28)(cid:3)
`(cid:55)(cid:76)(cid:80)(cid:72)(cid:29)(cid:3) (cid:28)(cid:29)(cid:19)(cid:19)(cid:3)(cid:68)(cid:17)(cid:80)(cid:17)(cid:3)
`(cid:51)(cid:79)(cid:68)(cid:70)(cid:72)(cid:29)(cid:3) (cid:38)(cid:82)(cid:88)(cid:85)(cid:87)(cid:85)(cid:82)(cid:82)(cid:80)(cid:3)(cid:26)(cid:15)(cid:3)(cid:20)(cid:28)(cid:87)(cid:75)(cid:3)(cid:41)(cid:79)(cid:82)(cid:82)(cid:85)(cid:3)
`(cid:45)(cid:88)(cid:71)(cid:74)(cid:72)(cid:29)(cid:3) (cid:43)(cid:82)(cid:81)(cid:17)(cid:3)(cid:48)(cid:68)(cid:91)(cid:76)(cid:81)(cid:72)(cid:3)(cid:48)(cid:17)(cid:3)(cid:38)(cid:75)(cid:72)(cid:86)(cid:81)(cid:72)(cid:92)(cid:3)
`
`(cid:48)(cid:40)(cid:39)(cid:55)(cid:53)(cid:50)(cid:49)(cid:44)(cid:38)(cid:182)(cid:54)(cid:3)(cid:50)(cid:51)(cid:51)(cid:50)(cid:54)(cid:44)(cid:55)(cid:44)(cid:50)(cid:49)(cid:3)(cid:55)(cid:50)(cid:3)(cid:36)(cid:42)(cid:36)(cid:182)(cid:54)(cid:3)(cid:48)(cid:50)(cid:55)(cid:44)(cid:50)(cid:49)(cid:3)
`(cid:41)(cid:50)(cid:53)(cid:3)(cid:54)(cid:56)(cid:48)(cid:48)(cid:36)(cid:53)(cid:60)(cid:3)(cid:45)(cid:56)(cid:39)(cid:42)(cid:48)(cid:40)(cid:49)(cid:55)(cid:3)(cid:6)(cid:21)(cid:3)(cid:11)(cid:44)(cid:49)(cid:57)(cid:36)(cid:47)(cid:44)(cid:39)(cid:44)(cid:55)(cid:60)(cid:12)
`(cid:38)(cid:36)(cid:54)(cid:40)(cid:3)(cid:49)(cid:50)(cid:17)(cid:3)(cid:38)(cid:19)(cid:26)(cid:16)(cid:19)(cid:19)(cid:24)(cid:25)(cid:26)(cid:3)(cid:48)(cid:48)(cid:38)(cid:3)
`
`(cid:20) (cid:21) (cid:22) (cid:23) (cid:24) (cid:25) (cid:26) (cid:27) (cid:28)
`
`(cid:20)(cid:19)
`(cid:20)(cid:20)
`(cid:20)(cid:21)
`(cid:20)(cid:22)
`(cid:20)(cid:23)
`(cid:20)(cid:24)
`(cid:20)(cid:25)
`(cid:20)(cid:26)
`(cid:20)(cid:27)
`(cid:20)(cid:28)
`(cid:21)(cid:19)
`(cid:21)(cid:20)
`(cid:21)(cid:21)
`(cid:21)(cid:22)
`(cid:21)(cid:23)
`(cid:21)(cid:24)
`(cid:21)(cid:25)
`(cid:21)(cid:26)
`(cid:21)(cid:27)
`DECHERT LLP
`ATTORNEYS AT LAW
`SILICON VALLEY
`
`Medtronic Exhibit 2001
`Cook v. Medtronic
`IPR2019-00123
`Page 00001
`
`

`

`Case3:07-cv-00567-MMC Document339 Filed03/13/09 Page2 of 33
`
`
`
`TABLE OF CONTENTS
`
`I.
`II.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`DECHERT LLP
`ATTORNEYS AT LAW
`SILICON VALLEY
`
`
`
`
`
`i
`
`Page
`
`
`B.
`
`C.
`
`D.
`
`E.
`
`2.
`
`3.
`
`3.
`
`4.
`
`5.
`
`2.
`
`INTRODUCTION .............................................................................................................. 1
`ARGUMENT ...................................................................................................................... 1
`A.
`Legal Standards Where the Summary Judgment Movant Bears the Burden
`of Proof at Trial....................................................................................................... 1
`AGA’s Request For Summary Judgment Regarding The Cragg II Work As
`§ 102(a) Prior Art Fails Because It Is Legally Flawed And Because, At A
`Minimum, It Raises Genuine Issues Of Material Fact............................................ 2
`1.
`Improper Evidence and Issues Of Material Fact As To Whether
`Each Asserted Claim Limitation Is Met Preclude a Finding of
`Invalidity on Summary Judgment ............................................................... 5
`The Evidence Demonstrates Dr. Cragg’s Lack Of Possession Of
`The Jervis Invention And Thus Precludes Summary Judgment Of
`Invalidity Under §102(a)............................................................................. 3
`Issues Of Material Fact As To Whether Dr. Cragg’s Work Was
`Public Preclude a Finding of Invalidity on Summary Judgment ................ 6
`AGA’s Request For Summary Judgment That Some Of The Asserted
`Claims Are Obvious Under § 103 Must Be Denied................................................ 7
`AGA’s Request for Summary Judgment That The Asserted Claims Are
`Obvious In Light Of The Combination Of Cragg I, Tanaka, And Miyauchi
`Must Fail Because Numerous Issues of Material Fact Exist................................... 8
`1.
`Obviousness Requires A Fact-Intensive Inquiry......................................... 9
`2.
`Material Issues Of Fact Regarding The Skill Level Of One Of
`Ordinary Skill In The Art Preclude A Finding of Obviousness on
`Summary Judgment................................................................................... 10
`Material Issues Of Fact Regarding The Scope And Content Of The
`Prior Art Preclude A Finding of Obviousness on Summary
`Judgment ................................................................................................... 10
`Material Issues Of Fact Regarding Whether The Differences
`Between the Prior Art and Invention Would Be Obvious And
`Whether There Is A Rational Basis To Combine Cited References
`Preclude A Finding of Obviousness on Summary Judgment ................... 13
`AGA Fails To Address Medtronic’s Objective Indicia Of
`Nonobviousness ........................................................................................ 13
`AGA’s Motion for Summary Judgment of Obviousness-Type Double
`Patenting Invalidity of the Jervis ‘141 Patent Should Be Denied......................... 14
`1.
`AGA’s Motion For Summary Judgment of Obviousness-Type
`Double Patenting Must be Denied Because AGA Did Not Plead
`The Defense .............................................................................................. 15
`AGA’s Motion for Summary Judgment of Obviousness-Type
`Double Patenting Must be Denied Because Use of the Patent That
`AGA Relies Upon to Support Its Defense Violates 35 U.S.C. § 121
`(“Safe Harbor”) ......................................................................................... 17
`a.
`The Law of Double Patenting and Restriction Requirements....... 18
`MEDTRONIC’S OPPOSITION TO AGA’S MOTION
`FOR SUMMARY JUDGMENT #2 (INVALIDITY)
`CASE NO. C07-00567 MMC
`
`IPR2019-00123 Page 00002
`
`

`

`Case3:07-cv-00567-MMC Document339 Filed03/13/09 Page3 of 33
`
`TABLE OF CONTENTS
`(CONTINUED)
`
`Page
`
`(1)
`(2)
`
`b.
`
`(2)
`
`(3)
`
`(4)
`
`Obviousness-Type Double Patenting................................ 18
`Restriction Requirements And Related Divisional
`Patent Applications ........................................................... 18
`Statutory “Safe Harbor” Under 35 U.S.C. § 121 .............. 19
`(3)
`A “Restriction Requirement” in the Jervis ‘378 “Parent”
`Patent Application Led to the Nonelected Claims in the
`Jervis ‘141 “Child/Divisional” Application And Triggered
`the “Safe Harbor” Provision of 35 U.S.C. § 121 .......................... 20
`(1)
`The Prosecution of the ‘378 “Parent” Patent
`Included a Restriction Requirement and Nonelected
`Claims Were Withdrawn................................................... 20
`The Nonelected Claims Were Then Pursued In a
`Divisional Application That Became the ‘141 Patent....... 21
`The Examiner Was Aware of the “Safe Harbor” and
`Never Rejected the ‘141 Claims Over the ‘378
`Claims ............................................................................... 22
`In Sum, Section 121 Precludes AGA’s Double
`Patenting Defense ............................................................. 22
`Putting Aside the Safe Harbor, AGA Fails to Establish that the
`Jervis ’141 Patent Claims Are Not “Patentably Distinct” From the
`Jervis ‘378 Patent Claims.......................................................................... 22
`CONCLUSION................................................................................................................. 25
`
`
`
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`3.
`
`III.
`
`28
`DECHERT LLP
`ATTORNEYS AT LAW
`SILICON VALLEY
`
`
`
`
`
`ii
`
`MEDTRONIC’S OPPOSITION TO AGA’S MOTION
`FOR SUMMARY JUDGMENT #2 (INVALIDITY)
`CASE NO. C07-00567 MMC
`
`IPR2019-00123 Page 00003
`
`

`

`
`
`
`
`Case3:07-cv-00567-MMC Document339 Filed03/13/09 Page4 of 33
`
` TABLE OF AUTHORITIES
`
`FEDERAL CASES
`
`Page
`
`Abbott Labs. v. Dey, L.P.,
`287 F.3d 1097 (Fed. Cir. 2002)......................................................................................... 23
`
`
`Abbott Labs. v. Sandoz, Inc.,
`544 F.3d 1341 (Fed. Cir. 2008)........................................................................................... 9
`
`
`American Hoist & Derrick Co. v. Sowa & Sons, Inc.,
`725 F.2d 1350 (Fed. Cir. 1984)..................................................................................... 1, 21
`
`
`Carella v. Starlight Archery & Pro Line Co.,
`804 F.2d 135 (Fed. Cir. 1986)............................................................................................. 4
`
`
`Carman Indus., Inc. v. Wahl,
`724 F.2d 932 (1983).......................................................................................................... 25
`
`
`Eibel Process Co. v. Minnesota & Ont. Paper Co.,
`261 U.S. 45, 43 S.Ct. 322 (1923).................................................................................... 3, 4
`
`
`Eisai Co LTD v. Dr. Reddy's Laboratories,
`533 F.3d 1353 (Fed. Cir. 2008)........................................................................................... 9
`
`
`Eli Lilly and Company v. Barr Laboratories,
`251 F.3d 955 (Fed. Cir. 2001)............................................................................... 18, 24, 25
`
`
`Finnigan Corp. v. International Trade Com'n.,
`180 F.3d 1354 (Fed. Cir. 1999)........................................................................................... 7
`
`
`Fraser v. Goodale,
`342 F.3d 1032 (9th Cir. 2003)............................................................................................. 2
`
`
`In re GPAC Inc.,
`57 F.3d 1573 (Fed. Cir. 1995)........................................................................................... 14
`
`
`General Foods Corp. v. Studiengesellschaft Kohle mbH,
`972 F.2d 1272 (Fed. Cir. 1992)................................................................................... 18, 25
`
`
`Houghton v. South,
`965 F.2d 1532 (9th Cir. 1992)............................................................................................. 1
`
`
`Invitrogen Corp. v. Clontech Labs., Inc.,
`429 F.3d 1052 (Fed. Cir. 2005)....................................................................................... 2, 4
`
`
`Juicy Whip, Inc. v. Orange Bang, Inc.,
`292 F.3d 728 (Fed. Cir. 2002)......................................................................................... 2, 5
`
`
`KSR Int'l Co. v. Teleflex, Inc.,
`127 S. Ct. 1727.................................................................................................................... 9
`
`
`In re Kaplan,
`789 F.2d 1574 (Fed. Cir. 1986)......................................................................................... 24
`
`
`
`
`
`
`
`iii
`
`MEDTRONIC’S OPPOSITION TO AGA’S MOTION
`FOR SUMMARY JUDGMENT #2 (INVALIDITY)
`CASE NO. C07-00567 MMC
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`DECHERT LLP
`ATTORNEYS AT LAW
`SILICON VALLEY
`
`IPR2019-00123 Page 00004
`
`

`

`Case3:07-cv-00567-MMC Document339 Filed03/13/09 Page5 of 33
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`DECHERT LLP
`ATTORNEYS AT LAW
`SILICON VALLEY
`
`Matsushita Electrical Industrial Co. v. Zenith Radio Corp.,
`475 U.S. 574, 106 S. Ct. 1348 (1986)................................................................................. 2
`
`
`Medtronic Vascular, Inc. v. Advanced Cardiovascular Sys., Inc., No. C 06-1066,
`2009 U.S. Dist. LEXIS 8948 (N.D. Cal., Feb. 6, 2009)................................................. 10, i
`
`
`Monarch Knitting Machinery Corp. v. Sulzer Morat GmbH,
`139 F.3d 877 (Fed. Cir. 1998)........................................................................................... 13
`
`
`Mycogen Plant Science, Inc. v. Monsanto Company,
`243 F.3d 1316 (Fed. Cir. 2001)....................................................................................... 3, 4
`
`
`Oddzon Products, Inc. v. Just Toys, Inc.,
`122 F.3d 1396 (Fed. Cir. 1997)........................................................................................... 7
`
`
`Pfizer, Inc. v. Teva Pharms USA, Inc.,
`518 F.3d 1353 (Fed. Cir. 2008)......................................................................................... 20
`
`
`Pharmacia & Upjohn Co. v. Mylan Pharms., Inc.,
`170 F.3d 1373 (Fed. Cir. 1999)......................................................................................... 23
`
`
`Ruiz v. A.B. Chance Co.,
`234 F.3d 654 ................................................................................................................. 9, 14
`
`
`Studiengesellschaft Kohle mbH v. Northern Petrochemical Co.,
`784 F.2d 351 (Fed. Cir. 1986)........................................................................................... 20
`
`
`Takeda Chemical v. Alphapharm,
`492 F.3d 1350 (Fed. Cir. 2007)........................................................................................... 9
`
`
`Union Carbide Co. v. Dow Chemical Co.,
`619 F. Supp. 1036 (D. Del. 1985)..................................................................................... 20
`
`
`W.L. Gore & Assocs., Inc. v. Garlock, Inc.,
`721 F.2d 1540 (Fed Cir. 1983)...................................................................................... 4, 11
`
`
`Welch v. General Motors Corp.,
`330 F. Supp. 80 (E.D. Va. 1970)....................................................................................... 23
`
`
`Woodland Trust v. Flowertree Nursery, Inc.,
`148 F.3d 1368, 47 USPQ2d 1363 (Fed.Cir.1998) .............................................................. 7
`
`
`
`FEDERAL STATUTES
`
`
`37 C.F.R. § 1.142 .................................................................................................................... 18, 19
`
`37 C.F.R. § 1.143 ......................................................................................................................... 19
`
`37 C.F.R. § 1.146 .......................................................................................................................... 19
`
`35 U.S.C. §§ 101........................................................................................................................... 15
`
`35 U.S.C. §§ 102........................................................................................................................... 16
`
`35 U.S.C. § 103............................................................................................................. 1, 3, 7, 8, 13
`MEDTRONIC’S OPPOSITION TO AGA’S MOTION
`FOR SUMMARY JUDGMENT #2 (INVALIDITY)
`CASE NO. C07-00567 MMC
`
`
`
`
`
`iv
`
`IPR2019-00123 Page 00005
`
`

`

`Case3:07-cv-00567-MMC Document339 Filed03/13/09 Page6 of 33
`
`
`
`
`35 U.S.C. § 282............................................................................................................................... 1
`
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`DECHERT LLP
`ATTORNEYS AT LAW
`SILICON VALLEY
`
`
`
`
`
`v
`
`MEDTRONIC’S OPPOSITION TO AGA’S MOTION
`FOR SUMMARY JUDGMENT #2 (INVALIDITY)
`CASE NO. C07-00567 MMC
`
`IPR2019-00123 Page 00006
`
`

`

`Case3:07-cv-00567-MMC Document339 Filed03/13/09 Page7 of 33
`
`
`
`I.
`
`INTRODUCTION
`AGA’s belated1 Motion (#2) for Summary Judgment of Invalidity Under 35 U.S.C.
`§§ 101 (“Double Patenting”), 102(a) (“Prior Use”) and 103 (“Obviousness”) (hereinafter,
`
`“Motion”) is really four separate motions. First, AGA argues for invalidity under 35 U.S.C.
`
`§ 102(a) based on the “Cragg II Work.” Second, AGA argues that the “Cragg II Work” renders
`
`obvious other claims under § 103. Third, AGA argues for invalidity under § 103 based on the
`
`combination of Cragg I, Tanaka and Miyauchi references. Fourth, AGA argues that all asserted
`
`claims of the ‘141 patent-in-suit are invalid under the judicially-created doctrine of non-statutory
`
`obviousness-type double patenting.
`
`Medtronic separately addresses each of these arguments below in Sections II.B, II.C, II.D,
`
`and II.E, respectively. In sum, AGA’s requests for summary judgment on its own affirmative
`
`defenses must fail because they are both legally unsound and riddled with numerous disputed
`
`issues of material fact. This is especially true because AGA is the party that bears the burden of
`
`proof at trial—a burden of clear and convincing evidence—and because the facts and inferences
`
`must be viewed in a light most favorable to Medtronic, as the non-movant. Thus, Medtronic
`
`respectfully requests that AGA’s Motion be denied in its entirety.
`II.
`
`ARGUMENT
`
`A.
`
`Legal Standards Where The Summary Judgment Movant Bears The Burden
`Of Proof At Trial
`
`AGA moves for summary judgment on its own affirmative defenses of invalidity.
`
`Accordingly, AGA “must come forward with evidence which would entitle it to a directed verdict
`
`if the evidence went uncontroverted at trial.” Houghton v. South, 965 F.2d 1532, 1536 (9th Cir.
`
`1992). Because Medtronic’s patents-in-suit are entitled to a presumption of validity pursuant to
`
`35 U.S.C. § 282, AGA must prove its invalidity contentions by clear and convincing evidence.
`
`See American Hoist & Derrick Co. v. Sowa & Sons, Inc., 725 F.2d 1350, 1360 (Fed. Cir. 1984).
`
`1 Contrary to the date indicated in its proof of service for AGA’s Motion, AGA belatedly filed
`and served this motion and associated papers on Saturday, February 28, 2009. The Court’s
`deadline for such motions, as set out in the Court’s Pretrial Preparation Order, was February 27,
`2009.
`
`
`
`
`
`1
`
`MEDTRONIC’S OPPOSITION TO AGA’S MOTION
`FOR SUMMARY JUDGMENT #2 (INVALIDITY)
`CASE NO. C07-00567 MMC
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`DECHERT LLP
`ATTORNEYS AT LAW
`SILICON VALLEY
`
`IPR2019-00123 Page 00007
`
`

`

`Case3:07-cv-00567-MMC Document339 Filed03/13/09 Page8 of 33
`
`
`
`Consequently, AGA faces a particularly high burden of establishing entitlement to summary
`
`judgment on its invalidity defenses, especially because all evidence and inferences must be
`
`resolved in Medtronic’s favor. Matsushita Electrical Industrial Co. v. Zenith Radio Corp., 475
`
`U.S. 574, 587, 106 S. Ct. 1348 (1986). Furthermore, conclusory assertions and mere attorney
`
`argument cannot support a movant’s burden on summary judgment. See Invitrogen Corp. v.
`
`Clontech Labs., Inc., 429 F.3d 1052, 1068 (Fed. Cir. 2005) (“Unsubstantiated attorney argument
`
`regarding the meaning of technical evidence is no substitute for competent, substantiated expert
`
`testimony. It does not, and cannot, support [the movant’s] burden on summary judgment.”). And
`
`finally, all evidence submitted in support of a summary judgment motion must be admissible at
`
`trial. Fraser v. Goodale, 342 F.3d 1032, 1036 (9th Cir. 2003).
`
`B.
`
`AGA’s Request For Summary Judgment Regarding The Cragg II Work As
`§ 102(a) Prior Art Fails Because It Is Legally Flawed And Because, At A
`Minimum, It Raises Genuine Issues Of Material Fact
`AGA alleges that all of the asserted claims of the Jervis patents-in-suit are invalid under
`
`§ 102(a) because Dr. Cragg and his associates publicly used the Jervis invention prior to Mr.
`Jervis’s invention date. See Motion at 10.2 In order to prevail on this defense, AGA must
`overcome the patents’ presumed validity with “clear and convincing evidence” that this work
`
`meets every limitation of the claimed invention. See Juicy Whip, Inc. v. Orange Bang, Inc., 292
`
`F.3d 728, 737-738 (Fed. Cir. 2002). In order to prove entitlement to summary judgment on such
`
`an affirmative defense, AGA must establish that no single disputed issue of material fact exists
`
`with respect to each element of its defense, when viewing all of the evidence in the light most
`
`favorable to Medtronic and taking all inferences in Medtronic’s favor. AGA has not done so.
`
`As an initial matter, AGA’s motion must fail because instead of analyzing the specific
`
`claim language, AGA paraphrases the claim language and neglects to address certain limitations.
`
`See AGA Motion at 8-9. Elsewhere, AGA only offers attorney argument as evidence. Id. at 9-
`10. Furthermore, because AGA is specifically relying on section 102(a)’s “prior use” provision,3
`
`2 Prior to filing its Motion, AGA never presented an invalidity claim chart detailing how it
`intended to use the work Dr. Cragg performed on vena cava filter as § 102(a) prior art, which is a
`failure to comply with this Court’s Patent Local Rule 3-3(c).
`3 AGA appears to only be asserting invalidity based on the work performed, which led up to the
`MEDTRONIC’S OPPOSITION TO AGA’S MOTION
`FOR SUMMARY JUDGMENT #2 (INVALIDITY)
`CASE NO. C07-00567 MMC
`
`2
`
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`DECHERT LLP
`ATTORNEYS AT LAW
`SILICON VALLEY
`
`IPR2019-00123 Page 00008
`
`

`

`Case3:07-cv-00567-MMC Document339 Filed03/13/09 Page9 of 33
`
`
`
`AGA must show that Dr. Cragg was in “possession” of the invention and that the invention was
`
`“public.” AGA has failed to prove these elements. The testimony of Dr. Cragg plainly
`
`demonstrates that he was not in possession of the Jervis invention. Dr. Cragg admitted that he
`
`had no concept of what “stress-induced martensite” was (an explicit limitation required by each
`
`asserted claim of the Jervis patents).
`
`At a minimum, genuine issues of material fact exist regarding whether (1) Dr. Cragg
`
`conceived or appreciated the Jervis invention; (2) Dr. Cragg’s work met every asserted claim
`
`limitation; and (3) Dr. Cragg’s work was “public.” These issues of material fact preclude a
`
`summary finding that the Dr. Cragg’s work during late 1982 to April 1983 was invalidating
`
`§ 102(a) prior art. AGA bears the burden of proof on these issues, and having failed to meet that
`
`burden, AGA’s motion should be denied.
`
`1.
`
`The Evidence Demonstrates Dr. Cragg’s Lack Of Possession Of The
`Jervis Invention And Thus Precludes Summary Judgment Of
`Invalidity Under §102(a)
`As explained in Medtronic’s Motion for Summary Judgment That The Cragg Filter
`
`Experiments Are Not Prior Art Under 35 U.S.C. § 102 or § 103 (Docket No. 285), AGA cannot
`
`demonstrate that the work Dr. Cragg performed regarding vena cava filters invalidates the Jervis
`
`patents in suit because Dr. Cragg clearly lacked a fundamental understanding of the Jervis
`
`invention. Medtronic vigorously disputes that Dr. Cragg was in possession of the Jervis
`
`invention. However, even if he were, any purported use of the Jervis invention was purely
`
`accidental, and accidental use is not enough under the law.
`
`Well-settled Supreme Court and Federal Circuit law states that “accidental results, not
`
`intended and not appreciated do not constitute anticipation.” Eibel Process Co. v. Minnesota &
`
`Ont. Paper Co., 261 U.S. 45, 66, 43 S.Ct. 322, 329 (1923) (emphasis added). See also Mycogen
`
`Plant Science, Inc. v. Monsanto Company, 243 F.3d 1316, 1336 (Fed. Cir. 2001). Furthermore,
`
`“Cragg II” publication (and not the publication itself). See Motion, caption page states “prior
`use”, and the legal section at 5 only discusses law on “knowledge or use.” “Cragg II” is the
`publication titled, Cragg et al., A New Percutaneous Vena Cava Filter, AJR (Sept. 1983), which
`discloses experiments using vena cava filters. The Cragg II publication cannot be used as prior
`art to Jervis, as Jervis has an invention date of at least as early as July 21, 1983, and Cragg II was
`not published until September 1983. See Ex.12.
`
`
`
`
`
`3
`
`MEDTR